MA38491B1 - Dihydropyridazine-3,5-dione derivative - Google Patents

Dihydropyridazine-3,5-dione derivative

Info

Publication number
MA38491B1
MA38491B1 MA38491A MA38491A MA38491B1 MA 38491 B1 MA38491 B1 MA 38491B1 MA 38491 A MA38491 A MA 38491A MA 38491 A MA38491 A MA 38491A MA 38491 B1 MA38491 B1 MA 38491B1
Authority
MA
Morocco
Prior art keywords
dihydropyridazine
dione derivative
prophylactic
salt
derivative
Prior art date
Application number
MA38491A
Other languages
French (fr)
Other versions
MA38491A1 (en
Inventor
Atsushi Kimbara
Yoshihito Ohtake
Naoki Okamoto
Yoshiyuki Ono
Hirotaka Kashiwagi
Takeo Harada
Nobuyuki Hori
Yoshihisa Murata
Kazutaka Tachibana
Shota Tanaka
Kenichi Nomura
Mitsuaki Ide
Eisaku Mizuguchi
Yasuhiro Ichida
Shuichi Ohtomo
Naoshi Horiba
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Priority claimed from PCT/JP2014/056778 external-priority patent/WO2014142273A1/en
Publication of MA38491A1 publication Critical patent/MA38491A1/en
Publication of MA38491B1 publication Critical patent/MA38491B1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un dérivé dihydropyridazine-3,5-dione, un de ses sels et des solvates du dérivé et du sel. L'invention concerne également les éléments suivants, lesquels contiennent l'un quelconque desdits composés comme principe actif : un médicament, une composition de médicament, un inhibiteur de transporteur phosphate dépendant du sodium, et un agent prophylactique et/ou thérapeutique ainsi qu'une méthode prophylactique et/ou thérapeutique contre l'hyperphosphatémie, l'hyperparathyroïdisme secondaire et l'insuffisance rénale chronique.The present invention relates to a dihydropyridazine-3,5-dione derivative, a salt thereof and solvates of the derivative and salt. The invention also relates to the following, which contain any of said compounds as an active ingredient: a drug, a drug composition, a sodium-dependent phosphate transporter inhibitor, and a prophylactic and / or therapeutic agent and a prophylactic and / or therapeutic method against hyperphosphatemia, secondary hyperparathyroidism and chronic renal failure.

MA38491A 2013-03-13 2014-03-13 Dihydropyridazine-3,5-dione derivative MA38491B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013051082 2013-03-13
PCT/JP2014/056778 WO2014142273A1 (en) 2013-03-13 2014-03-13 Dihydropyridazine-3,5-dione derivative

Publications (2)

Publication Number Publication Date
MA38491A1 MA38491A1 (en) 2016-12-30
MA38491B1 true MA38491B1 (en) 2017-09-29

Family

ID=56119094

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38491A MA38491B1 (en) 2013-03-13 2014-03-13 Dihydropyridazine-3,5-dione derivative

Country Status (2)

Country Link
AR (1) AR095394A1 (en)
MA (1) MA38491B1 (en)

Also Published As

Publication number Publication date
AR095394A1 (en) 2015-10-14
MA38491A1 (en) 2016-12-30

Similar Documents

Publication Publication Date Title
MX2018015892A (en) Boronic acid derivatives and therapeutic uses thereof.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12015501940A1 (en) Dihydropyridazine-3,5-dione derivative
EA201590224A1 (en) IMIDAZOTRIASINCARBONITRILE USED AS KINASE INHIBITORS
EP3483143A8 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
MX352672B (en) Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer.
MD4659B1 (en) Polymorph of SYK inhibitors
MA38039A1 (en) Céphem compounds substituted in position 2
MA39152B1 (en) 1,2-substituted cyclopentanes used as orexin receptor antagonists
MA47736B1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
PH12014502492A1 (en) Pyrazole compounds as sglt1 inhibitors
MX2015010619A (en) Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer.
MA43052B1 (en) Human Plasma Kallikrein Inhibitors
UA110577C2 (en) Agent for controlling plant diseases, a method for controlling plant diseases and a product for controlling diseases
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
PH12018500433A1 (en) Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same
GR1008186B (en) Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
EA201691574A1 (en) CONDENSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DOUBLE ALK AND FAK INHIBITOR
ME02299B (en) Azole derivative
MA38491A1 (en) Dihydropyridazine-3,5-dione derivative
EA201690797A1 (en) NEW CONNECTIONS
WO2013165898A3 (en) Compositions and methods for inhibiting resolvases
WO2014149973A3 (en) Compositions and methods for treating bone diseases
MA39719B1 (en) Pyrazoles substituted with trifluoromethyl as inhibitors of human plasma kallikrein
TH134786B (en) Crystalline form of benzyl benzene inhibitor for SGLT2.